Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-207: pemigatinib in advanced solid tumors with FGFR alterations
MOH_2020-02-02_008675Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemigatinib in Non-hematologic malignancy (3 cohorts), sponsored by Incyte. Started Aug 2019; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on MOH_2020-02-02_008675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-02_008675.